<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>BioMed Central</PublisherName>
    <PublisherLocation>London</PublisherLocation>
    <PublisherImprintName>BioMed Central</PublisherImprintName>
  </PublisherInfo>
  <Journal OutputMedium="Online">
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12885</JournalID>
      <JournalElectronicISSN>1471-2407</JournalElectronicISSN>
      <JournalTitle>BMC Cancer</JournalTitle>
      <JournalAbbreviatedTitle>BMC Cancer</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCB" Type="Primary">Biomedicine</JournalSubject>
        <JournalSubject Code="SCB11001" Priority="1" Type="Secondary">Cancer Research</JournalSubject>
        <JournalSubject Code="SCH33160" Priority="2" Type="Secondary">Oncology</JournalSubject>
        <JournalSubject Code="SCH59150" Priority="3" Type="Secondary">Surgical Oncology</JournalSubject>
        <JournalSubject Code="SCH27010" Priority="4" Type="Secondary">Health Promotion and Disease Prevention</JournalSubject>
        <JournalSubject Code="SCB0000X" Priority="5" Type="Secondary">Biomedicine general</JournalSubject>
        <JournalSubject Code="SCH00007" Priority="6" Type="Secondary">Medicine/Public Health, general</JournalSubject>
        <SubjectCollection Code="Biomedical and Life Sciences">SC3</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="Online">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>16</VolumeIDStart>
        <VolumeIDEnd>16</VolumeIDEnd>
        <VolumeIssueCount>1</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="Online">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>0</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2016</Year>
              <Month>12</Month>
            </CoverDate>
            <PricelistYear>2016</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>The Author(s)</CopyrightHolderName>
            <CopyrightYear>2016</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s12885-016-2397-8" OutputMedium="Online">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="Yes" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>2397</ArticleID>
            <ArticleDOI>10.1186/s12885-016-2397-8</ArticleDOI>
            <ArticleCitationID>363</ArticleCitationID>
            <ArticleSequenceNumber>362</ArticleSequenceNumber>
            <ArticleTitle Language="En" OutputMedium="All">MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system</ArticleTitle>
            <ArticleCategory>Research article</ArticleCategory>
            <ArticleCollection ID="AC_47bd92ad28b3a4e953a6bf7a9a990065" Type="SubjectSection">
              <ArticleCollectionTitle>Medical and radiation oncology</ArticleCollectionTitle>
            </ArticleCollection>
            <ArticleFirstPage>1</ArticleFirstPage>
            <ArticleLastPage>11</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>3</Day>
              </RegistrationDate>
              <Received>
                <Year>2015</Year>
                <Month>12</Month>
                <Day>1</Day>
              </Received>
              <Accepted>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>3</Day>
              </Accepted>
              <OnlineDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>10</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>The Author(s).</CopyrightHolderName>
              <CopyrightYear>2016</CopyrightYear>
              <License SubType="CC BY + CC0" Type="OpenAccess" Version="4.0">
                <SimplePara>
                           <Emphasis Type="Bold">Open Access</Emphasis>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ExternalRef>
                    <RefSource>http://creativecommons.org/licenses/by/4.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/licenses/by/4.0/" TargetType="URL"/>
                  </ExternalRef>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ExternalRef>
                    <RefSource>http://creativecommons.org/publicdomain/zero/1.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/publicdomain/zero/1.0/" TargetType="URL"/>
                  </ExternalRef>) applies to the data made available in this article, unless otherwise stated.</SimplePara>
              </License>
            </ArticleCopyright>
            <ArticleGrants Type="OpenChoice">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="OpenAccess"/>
              <BodyHTMLGrant Grant="OpenAccess"/>
              <BibliographyGrant Grant="OpenAccess"/>
              <ESMGrant Grant="OpenAccess"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Sehui</GivenName>
                  <FamilyName>Kim</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2 Aff3 Aff4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Soo</GivenName>
                  <GivenName>Jeong</GivenName>
                  <FamilyName>Nam</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Dohee</GivenName>
                  <FamilyName>Kwon</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Hannah</GivenName>
                  <FamilyName>Kim</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Eunyoung</GivenName>
                  <FamilyName>Lee</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Tae</GivenName>
                  <GivenName>Min</GivenName>
                  <FamilyName>Kim</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Dae</GivenName>
                  <GivenName>Seog</GivenName>
                  <FamilyName>Heo</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Sung</GivenName>
                  <GivenName>Hye</GivenName>
                  <FamilyName>Park</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1 Aff2 Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Chul</GivenName>
                  <GivenName>Woo</GivenName>
                  <FamilyName>Kim</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1 Aff2 Aff3" CorrespondingAffiliationID="Aff1" ORCID="http://orcid.org/0000-0001-8466-9681">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yoon</GivenName>
                  <GivenName>Kyung</GivenName>
                  <FamilyName>Jeon</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>+82-2-2072-1347</Phone>
                  <Fax>+82-2-743-5530</Fax>
                  <Email>junarplus@chol.com</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Department of Pathology</OrgDivision>
                <OrgName>Seoul National University Hospital, Seoul National University College of Medicine</OrgName>
                <OrgAddress>
                  <Street>101 Daehak-ro, Jongno-gu</Street>
                  <City>Seoul</City>
                  <Postcode>03080</Postcode>
                  <Country Code="KR">Republic of Korea</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>The Tumor Immunity Medical Research Center</OrgDivision>
                <OrgName>Seoul National University College of Medicine</OrgName>
                <OrgAddress>
                  <City>Seoul</City>
                  <Country Code="KR">Republic of Korea</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Tumor Microenvironment Global Core Research Center</OrgDivision>
                <OrgName>Seoul National University</OrgName>
                <OrgAddress>
                  <City>Seoul</City>
                  <Country Code="KR">Republic of Korea</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgName>Department of Pathology, Asan Medical Center</OrgName>
                <OrgAddress>
                  <City>Seoul</City>
                  <Country Code="KR">Republic of Korea</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff5">
                <OrgDivision>Department of Internal Medicine</OrgDivision>
                <OrgName>Seoul National University Hospital, Seoul National University College of Medicine</OrgName>
                <OrgAddress>
                  <City>Seoul</City>
                  <Country Code="KR">Republic of Korea</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <AbstractSection ID="ASec1">
                <Heading>Background</Heading>
                <Para ID="Par1">Primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) is a distinct clinicopathological entity with a poor prognosis. Concurrent MYC and BCL2 overexpression predicts inferior prognosis in systemic DLBCLs. However, the prognostic significance of MYC and BCL2 in PCNS-DLBCL remains elusive.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec2">
                <Heading>Methods</Heading>
                <Para ID="Par2">Immunohistochemistry (IHC) of MYC, BCL2 and BCL6 was performed on tumor samples from 114 patients with PCNS-DLBCL. IHC score was assigned based on the proportion of immunostained cells.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec3">
                <Heading>Results</Heading>
                <Para ID="Par3">MYC, BCL2, and BCL6 IHC scores were 18.16 ± 19.58, 58.86 ± 35.07, and 39.39 ± 37.66 % (mean ± SD), respectively. Twenty-one cases (18.1 %) were designated as MYC-positive with a cutoff score of 40. BCL2 positivity was found in 87 cases (75.0 %) using a cutoff score of 30. MSKCC (Memorial Sloan-Kettering Cancer Center prognostic model) class 2 and 3 had higher rates of MYC and/or BCL2 positivity (MYC, <Emphasis Type="Italic">P</Emphasis> = 0.012; BCL2, <Emphasis Type="Italic">P</Emphasis> = 0.008; dual-positive, <Emphasis Type="Italic">P</Emphasis> = 0.022). Poor KPS (Karnofsky Performance Status score &lt;70), multifocal disease, Nottingham-Barcelona score ≥2, and MSKCC class 2 and 3 were related to shorter progression-free survival (PFS) (<Emphasis Type="Italic">P</Emphasis> = 0.001, 0.037, 0.001, and 0.008, respectively). Patients with older age (&gt;60 years) showed poorer overall survival (OS) (<Emphasis Type="Italic">P</Emphasis> = 0.020). MYC positivity was associated with poor PFS (<Emphasis Type="Italic">P</Emphasis> = 0.027), while patients with BCL2 positivity exhibited a shorter OS (<Emphasis Type="Italic">P</Emphasis> = 0.010). Concomitant MYC and BCL2 positivity was related to poor PFS (<Emphasis Type="Italic">P</Emphasis> = 0.041), while the lack of both MYC and BCL2 expression was related to prolonged OS (<Emphasis Type="Italic">P</Emphasis> = 0.014). MYC and BCL2 expression had no independent prognostic implication by multivariate analysis in overall patients with PCNS-DLBCL. However, among patients treated with combined high-dose methotrexate, vincristine and procarbazine and radiotherapy, dual MYC and BCL2 overexpression (a cutoff score of 60) was an independent poor prognostic indicator (<Emphasis Type="Italic">P</Emphasis> = 0.010).</Para>
              </AbstractSection>
              <AbstractSection ID="ASec4">
                <Heading>Conclusions</Heading>
                <Para ID="Par4">Evaluation of MYC and BCL2 expression may be helpful for the determination of PCNS-DLBCL prognosis.</Para>
              </AbstractSection>
            </Abstract>
            <KeywordGroup Language="En" OutputMedium="All">
              <Heading>Keywords</Heading>
              <Keyword>Primary central nervous system lymphoma</Keyword>
              <Keyword>Diffuse large B-cell lymphoma</Keyword>
              <Keyword>MYC</Keyword>
              <Keyword>BCL2</Keyword>
              <Keyword>Prognosis</Keyword>
            </KeywordGroup>
            <ArticleNote Type="ESMHint">
              <Heading>Electronic supplementary material</Heading>
              <SimplePara>The online version of this article (doi:<ExternalRef>
                  <RefSource>10.1186/s12885-016-2397-8</RefSource>
                  <RefTarget Address="10.1186/s12885-016-2397-8" TargetType="DOI"/>
                </ExternalRef>) contains supplementary material, which is available to authorized users.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <Body>
            <Section1 ID="Sec1" Type="Introduction">
              <Heading>Background</Heading>
              <Para ID="Par5">Primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) is a distinct subtype of DLBCL that primarily arises in the intracranial and intraocular areas [<CitationRef CitationID="CR1">1</CitationRef>]. PCNS-DLBCL has a poorer prognosis than systemic DLBCL. This may be due to the fact the blood brain barrier makes it difficult for chemotherapeutic agents to penetrate, that the site of involvement is immune-privileged, and that the cell of origin is mainly a non-germinal center B-cell [<CitationRef CitationID="CR2">2</CitationRef>].</Para>
              <Para ID="Par6">To determine the prognosis of PCNS-DLBCL, several scoring systems, which are mostly based on clinical features, have been recommended. The international extranodal lymphoma study group (IELSG) suggested that age (&gt;60 years), performance status (PS) (≥2), elevated serum lactate dehydrogenase (LDH) levels, a high cerebrospinal fluid (CSF) protein concentration, and involvement of deep brain structures (periventricular regions, basal ganglia, brain stem, and/or cerebellum) are significantly associated with a poor prognosis. This scoring system was validated in patients treated with high-dose methotrexate-based chemotherapy [<CitationRef CitationID="CR3">3</CitationRef>]. In contrast, the Nottingham/Barcelona score, which incorporates age ≥60, PS ≥ 2 and multifocal disease, showed a prognostic impact in patients treated with CHOD/BVAM or BVAM chemotherapy followed by radiotherapy [<CitationRef CitationID="CR4">4</CitationRef>]. Meanwhile, the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model is able to classify patients into class 1 (age ≤50 years), class 2 (age &gt;50; Karnofsky performance score (KPS) ≥70) and class 3 (age &gt;50; KPS &lt;70) with prognostic significance [<CitationRef CitationID="CR5">5</CitationRef>]. However, there is still no consensus about prognostic scoring systems in PCNS-DLBCL. Moreover, the pathological and biological prognostic factors for PCNS-DLBCL remain unknown.</Para>
              <Para ID="Par7">Recent studies have shown that concomitant MYC and BCL2 expression predicts inferior survival in systemic DLBCL patients treated with rituximab-CHOP [<CitationRef CitationID="CR6">6</CitationRef>, <CitationRef CitationID="CR7">7</CitationRef>]. Moreover, coexpression MYC and BCL2 was found to have prognostic value in patients with DLBCL independent of cell of origin, but is related to a high-risk gene expression signature [<CitationRef CitationID="CR7">7</CitationRef>]. Thus, MYC and BCL2 coexpression status is very helpful for risk stratification along with the international prognostic index (IPI) score in systemic DLBCL [<CitationRef CitationID="CR6">6</CitationRef>, <CitationRef CitationID="CR7">7</CitationRef>]. Meanwhile, only a few studies are available on MYC and BCL2 expression in PCNS-DLBCL [<CitationRef CitationID="CR8">8</CitationRef>–<CitationRef CitationID="CR10">10</CitationRef>]. However, these studies have demonstrated conflicting results in terms of prognostic significance of MYC and BCL2 status in patients with PCNS-DLBCL. A study on 47 patients with PCNS-DLBCL showed that MYC, BCL2 and BCL6 were frequently coexpressed but had no prognostic significance [<CitationRef CitationID="CR8">8</CitationRef>]. Another study demonstrated that MYC expression, with or without BCL2 coexpression, was not predictive of clinical outcome in 59 patients with PCNS-DLBCL [<CitationRef CitationID="CR9">9</CitationRef>]. In contrast, MYC expression was associated with poor prognosis in a study on 42 patients with PCNS-DLBCL [<CitationRef CitationID="CR10">10</CitationRef>]. Thus, we comprehensively investigated the expression of MYC, BCL2 and BCL6, and their association with clinicopathological characteristics and prognosis in a large cohort of PCNS-DLBCL patients.</Para>
            </Section1>
            <Section1 ID="Sec2" Type="MaterialsAndMethods">
              <Heading>Methods</Heading>
              <Section2 ID="Sec3">
                <Heading>Patients</Heading>
                <Para ID="Par8">In total, 114 patients diagnosed with PCNS-DLBCL managed at Seoul National University Hospital (SNUH, Seoul, Korea) between 2000 and 2012 were included in this study. Pathologic diagnosis was performed according to the current World Health Organization (WHO) classification of Tumors of Hematopoietic and Lymphoid Tissues [<CitationRef CitationID="CR1">1</CitationRef>]. Tumor tissues were obtained before treatment in all patients. Clinicopathological and survival data were retrieved from medical records by three hemato-oncologists (E.L, T.M.K and D.S.H) and from the review of pathological material by three pathologists (S.K., S.J.N and Y.K.J). This study followed the World Medical Association Declaration of Helsinki recommendations and was approved by the Institutional Review Board (IRB) of SNUH (IRB No. 1506-080-681). Informed consent for participation in the study was waived by the IRB of SNUH on the basis that this study was a retrospective study using archived material and did not pose increased risk to the patients.</Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>Immunohistochemistry</Heading>
                <Para ID="Par9">Immunohistochemistry (IHC) was performed using antibodies against MYC (clone EP121, Cell Marque, Rocklin, CA, USA), BCL2 (clone 124, DAKO, Carpinteria, CA, USA), BCL6 (clone LN22, Novocastra, Newcastle, United Kingdom), CD10 (clone 56C6, Novocastra), and MUM1 (clone Ma695, Novocastra). IHC staining was performed using the Ventana Benchmark XT system (Ventana Medical Systems, Tucson, AZ, USA) or a Bond-Max automated immunostainer (Leica Microsystems, Melbourne, Australia). Cell of origin was assessed according to the Hans criteria [<CitationRef CitationID="CR11">11</CitationRef>]. IHC score was determined to be the percentage of tumor cells with robust immunostaining evaluated by 10 % increments. Cutoff values (i.e. IHC scores) of ≥40 % for MYC, ≥30 and ≥60 % for BCL2 and ≥50 % for BCL6 were determined to have discriminant prognostic power based on the receiver operator characteristic (ROC) curves and were thus used for classifying cases into MYC-, BCL2- or BCL6-negative and-positive groups.</Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>Statistical analysis</Heading>
                <Para ID="Par10">A comparison of clinicopathological parameters was performed by Chi-square, Fisher’s exact, and Student’s <Emphasis Type="Italic">t</Emphasis>-tests. PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test. Univariate and multivariate analysis were performed using the Cox proportional hazards regression model. All statistical analyses were performed using SPSS software (version 21; IBM Corp., Armonk, NY, USA). Two-sided <Emphasis Type="Italic">P</Emphasis> values &lt;0.05 were considered statistically significant.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec6" Type="Results">
              <Heading>Results</Heading>
              <Section2 ID="Sec7">
                <Heading>Clinicopathological features of patients with PCNS-DLBCL</Heading>
                <Para ID="Par11">The clinicopathological characteristics and treatment modalities of 114 patients with PCNS-DLBCL are summarized in Table <InternalRef RefID="Tab1">1</InternalRef>. The patient population included 65 (57.0 %) males and 49 (43.0 %) females with a median age of 61 years (range 10–82 years). Most patients had experienced neurologic deficits as the initial symptom (78/114, 68.4 %), and had a KPS score ≥70 (97/111, 87.4 %) and an ECOG PS &lt;2 (73/112, 65.2 %) at diagnosis. Deep structure involvement (84/114, 73.7 %) and multifocality (72/114, 63.2 %) were frequently observed. The majority (89/113, 78.8 %) of cases were of non-germinal center B-cell origin, which was higher than in systemic DLBCL patients in our institute (63 %) [<CitationRef CitationID="CR12">12</CitationRef>]. In total, 52.7 % (48/91) of patients had an IELSG score ≥ 3, 52.7 % (59/112) of patients had a Nottingham-Barcelona score ≥2 and 79.8 % (91/112) of patients were classified as MSKCC class 2 or 3. Most patients received high-dose methotrexate-containing chemotherapy including high-dose methotrexate, vincristine and procarbazine (MVP) (79/97, 81.4 %) or high-dose methotrexate (HD-MTX) (14/97, 14.4 %), and 58.8 % (57/97) of patients were treated with combined MVP and radiotherapy.<Table Float="Yes" ID="Tab1">
                    <Caption Language="En">
                      <CaptionNumber>Table 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Clinicopathological characteristics of patients and treatment modalities</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="7">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <colspec align="left" colname="c7" colnum="7"/>
                      <thead>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Variables<Superscript>a</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c2" morerows="1"/>
                          <entry colname="c3">
                            <SimplePara>n (%)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>5YRS</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>PFS, <Emphasis Type="Italic">P</Emphasis>
                                            <Superscript>d</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>5YRS</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>OS, <Emphasis Type="Italic">P</Emphasis>
                                            <Superscript>d</Superscript>
                                          </SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c3">
                            <SimplePara>(Total = 114)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>PFS (SD)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>OS (SD)</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Age (yr)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>≤50</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>23 (20.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.684 (0.108)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.072</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.909 (0.043)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.126</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>&gt;50</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>91 (79.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.334 (0.090)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.698 (0.086)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Age (yr)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>≤60</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>55 (48.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.498 (0.081)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.585</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.854 (0.065)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.014</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>&gt;60</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>59 (51.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.217 (0.167)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.569 (0.172)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Sex</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>M</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>65 (57.0)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.452 (0.086)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.708</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.849 (0.054)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.156</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>F</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>49 (43.0)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.460 (0.112)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.452 (0.168)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="2">
                            <SimplePara>Initial Symptoms</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Headache &amp;vomiting</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>30 (26.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.609 (0.114)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="2">
                            <SimplePara>0.400</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.870 (0.071)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="2">
                            <SimplePara>0.266</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Seizure</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>6 (5.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.000 (0.000)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>100.0</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Neurologic deficit</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>78 (68.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.387 (0.085)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.697 (0.085)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>ECOG PS</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0, 1</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>73 (65.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.425 (0.086)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.818</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.789 (0.075)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.247</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>2–4</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>39 (34.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.511 (0.135)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.752 (0.079)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>KPS</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>≥70</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>97 (87.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.468 (0.082)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.001</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.760 (0.065)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.854</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>&lt;70</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>14 (12.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.259 (0.144)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.821 (0.117)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>B Symptoms</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Absent</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>109 (95.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.452 (0.073)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.284</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.768 (0.061)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.558</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Present</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>5 (4.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.333 (0.272)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.800 (0.179)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Serum LDH</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Normal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>68 (63.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.223 (0.087)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.005</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.767 (0.102)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.201</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Elevated</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>39 (36.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.675 (0.102)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.760 (0.100)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Cell of origin</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>GCB</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>24 (21.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.689 (0.120)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.073</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.795 (0.092)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.957</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Non-GCB</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>89 (78.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.383 (0.082)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.756 (0.074)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Involvement of deep structure</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Absent</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>30 (26.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.441 (0.161)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.219</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.758 (0.129)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.640</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Present</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>84 (73.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.433 (0.078)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.762 (0.070)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Extent of disease</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Unifocal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>42 (36.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.553 (0.119)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.037</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.753 (0.137)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.603</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Multifocal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>72 (63.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.368 (0.088)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.782 (0.062)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Ocular involvement</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Absent</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>101 (89.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.485 (0.072)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.985</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.872 (0.046)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.466</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Present</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>12 (10.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.233 (0.190)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.525 (0.204)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>CSF protein</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Normal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>39 (42.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.291 (0.142)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.988</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.675 (0.141)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.340</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Elevated</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>53 (57.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.467 (0.090)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.849 (0.058)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>CSF cytology</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Negative</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>82 (85.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.356 (0.083)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.281</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.774 (0.066)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.693</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Positive</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>14 (14.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.608 (0.158)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.711 (0.180)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>IELSG</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0–2</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>43 (47.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.229 (0.100)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.093</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.853 (0.101)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.054</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>3–5</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>48 (52.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.638 (0.088)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.736 (0.074)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Nottingham– Barcelona</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0–1</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>53 (47.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.604 (0.097)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.001</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.807 (0.080)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.188</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>2–3</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>59 (52.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.264 (0.098)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.723 (0.084)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>MSKCC class</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>1</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>21 (18.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.760 (0.106)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.008</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.847 (0.108)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.157</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>2–3</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>91 (79.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.340 (0.086)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.688 (0.095)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Radiotherapy</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Not done</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>36 (31.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.586 (0.142)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.854</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.758 (0.086)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.057</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Done</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>78 (68.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.416 (0.080)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.787 (0.068)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="2">
                            <SimplePara>Chemotherapy</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>MVP<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>79 (81.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.431 (0.084)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="2">
                            <SimplePara>0.519</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.772 (0.072)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="2">
                            <SimplePara>0.940</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>HD-MTX</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>14 (14.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.442 (0.176)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.791 (0.138)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Others<Superscript>c</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>4 (4.1)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.750 (0.217)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>100.0</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Rituximab</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Not done</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>103 (90.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.453 (0.074)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.756</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.748 (0.067)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.503</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Done</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>11 (9.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.333 (0.248)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.909 (0.087)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>IT-MTX</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Not done</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>89 (78.1)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.412 (0.092)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.649</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.743 (0.076)</SimplePara>
                          </entry>
                          <entry colname="c7" morerows="1">
                            <SimplePara>0.415</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Done</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>25 (21.9)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.457 (0.114)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.832 (0.089)</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                    <tfooter>
                      <SimplePara>
                                    <Emphasis Type="Italic">Abbreviations</Emphasis>: <Emphasis Type="Italic">ECOG PS</Emphasis> The Eastern Cooperative Oncology Group performance score, <Emphasis Type="Italic">KPS</Emphasis> Karnofsky performance status score, <Emphasis Type="Italic">LDH</Emphasis> lactate dehydrogenase, <Emphasis Type="Italic">GCB</Emphasis> germinal center B cell-like, <Emphasis Type="Italic">CSF</Emphasis> cerebrospinal fluid, <Emphasis Type="Italic">IELSG</Emphasis> the International Extranodal Lymphoma Study group, <Emphasis Type="Italic">MSKCC</Emphasis> Memorial Sloan Kettering Cancer Center, <Emphasis Type="Italic">MVP</Emphasis> combined chemotherapy regimen of high-dose methotrexate, vincristine and procarbazine, <Emphasis Type="Italic">HD-MTX</Emphasis> high-dose methotrexate, <Emphasis Type="Italic">IT-MTX</Emphasis> intrathecal methotrexate, <Emphasis Type="Italic">PFS</Emphasis> progression-free survival, <Emphasis Type="Italic">OS</Emphasis> overall survival</SimplePara>
                      <SimplePara>
                                    <Superscript>a</Superscript>Some cases have missing values that lacked the information about the variables</SimplePara>
                      <SimplePara>
                                    <Superscript>b</Superscript>Includes 8 patients who received rituximab-MVP</SimplePara>
                      <SimplePara>
                                    <Superscript>c</Superscript>Others include COPADM and CHOP</SimplePara>
                      <SimplePara>
                                    <Superscript>d</Superscript>PFS and OS were analyzed using the Kaplan-Meier method with the log-rank test</SimplePara>
                    </tfooter>
                  </Table>
                        </Para>
                <Para ID="Par12">The five-year PFS and OS based on clinicopathological variables are shown in Table <InternalRef RefID="Tab1">1</InternalRef>. Older patients (age &gt;60) had a shorter OS (<Emphasis Type="Italic">P</Emphasis> = 0.014), and patients with KSP &lt;70 and multifocal lesions had a shorter PFS (<Emphasis Type="Italic">P</Emphasis> = 0.001 and 0.037, respectively). The non-germinal center phenotype tended to have a poorer PFS, but this did not reach statistical significance (<Emphasis Type="Italic">P</Emphasis> = 0.073). Patients with a Nottingham-Barcelona score ≥2 or MSKCC class 2 or 3 had a shorter PFS (<Emphasis Type="Italic">P</Emphasis> = 0.001 and 0.008, respectively). The IELSG scoring system showed inconclusive results, in that patients with an IELSG score ≥3 had a tendency to show better PFS (<Emphasis Type="Italic">P</Emphasis> = 0.093) and worse OS (<Emphasis Type="Italic">P</Emphasis> = 0.054). The treatment modalities including the chemotherapeutic agent, use of radiotherapy, rituximab or intrathecal-MTX were not associated with patient clinical outcomes in the total patient group. However, in the MVP-treated group, patients receiving radiotherapy showed a better prognosis than did those who did not receive radiotherapy (for PFS, <Emphasis Type="Italic">P</Emphasis> = 0.078; for OS, <Emphasis Type="Italic">P</Emphasis> = 0.001) (data not shown).</Para>
              </Section2>
              <Section2 ID="Sec8">
                <Heading>Relationship between MYC, BCL2, and BCL6 expression and clinicopathological features</Heading>
                <Para ID="Par13">Representative IHC images of MYC, BCL2 and BCL6 are shown in Fig. <InternalRef RefID="Fig1">1</InternalRef>. The proportion of tumor cells expressing MYC (i.e., MYC IHC score) was estimated as 18.16 ± 19.58 % (mean ± SD) (median: 10, range: 0-80 %). Using a cutoff score of 40, 21 (18.1 %) of the 114 cases were placed in the MYC-positive group. The BCL2 IHC score was also measured, with an average score of 58.86 ± 35.07 % (median: 70, range: 0-100 %); 87 (75.0 %) and 68 (59.6 %) of the 114 cases were classified as BCL2-positive using cutoff score of 30 and 60, respectively. The average BCL6 IHC score was 39.39 ± 37.66 % (median: 25, range: 0–100 %), and 51 (44.0 %) of the 114 cases were classified as BCL6-positive using a cutoff score of 50. Taken together, MYC and BCL2 dual-positive cases accounted for 15.8 % (18/114) of PCNS-DLBCLs, while MYC and BCL2 dual-negative cases accounted for 21.9 % (25/114) with a BCL2 cutoff score of 30. In addition, MYC and BCL2 IHC scores were positively correlated (Spearman’s rho = 0.320, <Emphasis Type="Italic">P</Emphasis> = 0.001), but MYC and BCL6, and BCL2 and BCL6 IHC scores were not (Additional file <InternalRef RefID="MOESM1">1</InternalRef>: Figure S1).<Figure Category="Standard" Float="Yes" ID="Fig1">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Representative immunohistochemical images of MYC, BCL2 and BCL6 expression in PCNS-DLBCL tumors. Representative IHC images of MYC-negative (<Emphasis Type="Bold">A</Emphasis>-<Emphasis Type="Bold">1</Emphasis>) and <Emphasis Type="Bold">-</Emphasis>positive (<Emphasis Type="Bold">A</Emphasis>-<Emphasis Type="Bold">2</Emphasis>) cases, BCL2-negative (<Emphasis Type="Bold">B</Emphasis>-<Emphasis Type="Bold">1</Emphasis>) and -positive (<Emphasis Type="Bold">B</Emphasis>-<Emphasis Type="Bold">2</Emphasis>) cases, and BCL6-negative (<Emphasis Type="Bold">C</Emphasis>-<Emphasis Type="Bold">1</Emphasis>) and -positive (<Emphasis Type="Bold">C</Emphasis>-<Emphasis Type="Bold">2</Emphasis>) cases</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO1">
                      <ImageObject Color="Color" FileRef="MediaObjects/12885_2016_2397_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
                <Para ID="Par14">Among the 57 patients treated with combined MVP and radiotherapy (MVP-RT hereafter), 12.3 % (7/57) were designated as MYC-positive using a cutoff score of 40, and 71.9 % (41/57) and 54.4 % (31/57) of the cases were classified as BCL2-positive using cutoff scores of 30 and 60, respectively; 49.1 % (28/57) of the cases were classified as BCL6-positive using a cutoff score of 50. Taken together, MYC and BCL2 dual-positive cases accounted for 12.3 % (7/57; with a BCL2 cutoff score of 30) and 10.5 % (6/57; with a BCL2 cutoff score of 60), while MYC and BCL2 dual-negative cases accounted for 28.1 % (16/57; with a BCL2 cutoff score of 30) and 43.9 % (25/57; with a BCL2 cutoff score of 60) of patients in the MVP-RT group.</Para>
                <Para ID="Par15">The relationship between MYC, BCL2 and BCL6 expression and clinicopathological features are summarized in Table <InternalRef RefID="Tab2">2</InternalRef> and Additional file <InternalRef RefID="MOESM2">2</InternalRef>: Table S1. Patients aged &gt; 60 years tended to be BCL2-positive more often (<Emphasis Type="Italic">P</Emphasis> = 0.051), and higher MSKCC class was significantly associated with MYC and BCL2 positivity separately (<Emphasis Type="Italic">P</Emphasis> = 0.012 and 0.008, respectively) (Table <InternalRef RefID="Tab2">2</InternalRef>) and with MYC and BCL2 coexpression (<Emphasis Type="Italic">P</Emphasis> = 0.022 by Fisher’s Exact Test) (data not shown). Cases of non-germinal cell origin were BCL2-positive more often (<Emphasis Type="Italic">P</Emphasis> = 0.005), but were BCL6-negative (<Emphasis Type="Italic">P</Emphasis> = 0.013) (Table <InternalRef RefID="Tab2">2</InternalRef> and Additional file <InternalRef RefID="MOESM2">2</InternalRef>: Table S1). There were no other correlations between clinical parameters and MYC, BCL2 or BCL6 expression. In addition, MYC, BCL2 or BCL6 positivity did not differ by treatment modality (data not shown). Among the patients of MVP-RT group, no significant relationship was observed between clinicopathological features and the MYC and BCL2 expression status except for higher expression of MYC in female than in male (<Emphasis Type="Italic">P</Emphasis> = 0.039) (data not shown).<Table Float="Yes" ID="Tab2">
                    <Caption Language="En">
                      <CaptionNumber>Table 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Correlation of MYC and BCL2 expression and clinicopathological variables</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="8">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <colspec align="left" colname="c7" colnum="7"/>
                      <colspec align="left" colname="c8" colnum="8"/>
                      <thead>
                        <row>
                          <entry colname="c1"/>
                          <entry colname="c2"/>
                          <entry nameend="c4" namest="c3">
                            <SimplePara>MYC, n (%)</SimplePara>
                          </entry>
                          <entry nameend="c8" namest="c5">
                            <SimplePara>BCL2, n (%)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>Variables<Superscript>a</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c2"/>
                          <entry colname="c3">
                            <SimplePara>&lt;40</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>≥40</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>
                              <Emphasis Type="Italic">P</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>&lt;30</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>≥30</SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>
                              <Emphasis Type="Italic">P</Emphasis>
                            </SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry colname="c1">
                            <SimplePara>Age (yr)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>mean ± SD</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>57.6 ± 14.6</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>63.1 ± 7.6</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>0.097</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>50.4 ± 19</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>61.3 ± 10.4</SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>&lt;0.001</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Age (yr)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>≤50</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>22 (95.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>1 (4.3)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.069</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>11 (47.8)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>12 (52.2)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.004</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>&gt;50</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>71 (78)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>20 (22)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>17 (18.7)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>74 (81.3)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Age (yr)</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>≤60</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>46 (83.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>9 (16.4)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.584</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>18 (32.7)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>37 (67.3)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.051</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>&gt;60</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>47 (79.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>12 (20.3)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>10 (16.9)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>49 (83.1)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Sex</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>M</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>55 (84.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>10 (15.4)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.335</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>20 (30.8)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>45 (69.2)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.076</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>F</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>38 (77.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>11 (22.4)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>8 (16.3)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>41 (83.7)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>ECOG PS</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0, 1</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>62 (84.9)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>11 (15.1)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.172</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>19 (26)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>54 (74)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.731</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>2–4</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>29 (74.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>10 (25.6)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>9 (23.1)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>30 (76.9)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>KPS</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>≥70</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>81 (83.5)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>16 (16.5)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.136</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>24 (24.7)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>73 (75.3)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>&gt;0.999</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>&lt;70</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>9 (64.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>5 (35.7)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>3 (21.4)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>11 (78.6)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>B symptoms</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Absent</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>88 (80.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>21 (19.3)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.582<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>26 (23.9)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>83 (76.1)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.595<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Present</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>5 (100)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0 (0)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>2 (40)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>3 (60)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Serum LDH</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Normal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>54 (79.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>14 (20.6)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.506</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>19 (27.9)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>49 (72.1)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.582</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Elevated</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>33 (84.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>6 (15.4)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>9 (23.1)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>30 (76.9)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Cell of origin</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>GCB</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>22 (91.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>2 (8.3)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.236<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>11 (45.8)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>13 (54.2)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.005</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Non-GCB</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>70 (78.7)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>19 (21.3)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>16 (18)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>73 (82)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Involvement of deep structure</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Absent</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>24 (80)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>6 (20)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.795</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>6 (20)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>24 (80)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.499</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Present</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>69 (82.1)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>15 (17.9)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>22 (26.2)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>62 (73.8)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Extent of disease</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Unifocal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>34 (81)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>8 (19)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.895</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>11 (26.2)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>31 (73.8)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.758</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Multifocal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>59 (81.9)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>13 (18.1)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>17 (23.6)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>55 (76.4)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Ocular involvement</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Absent</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>82 (81.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>19 (18.8)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>&gt;0.999<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>25 (24.8)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>76 (75.2)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>&gt;0.999<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Present</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>10 (83.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>2 (16.7)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>3 (25)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>9 (75)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>CSF protein</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Normal</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>31 (79.5)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>8 (20.5)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.844</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>8 (20.5)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>31 (79.5)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.157</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Elevated</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>43 (81.1)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>10 (18.9)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>18 (34.0)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>35 (66.0)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>CSF cytology</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>Negative</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>66 (80.5)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>16 (19.5)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>&gt;0.999<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>19 (23.2)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>63 (76.8)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.121</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>Positive</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>11 (78.6)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>3 (21.4)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>6 (42.9)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>8 (57.1)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>IELSG</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0–2</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>35 (81.4)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>8 (18.6)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.790</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>13 (30.2)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>30 (69.8)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.740</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>3–5</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>38 (79.2)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>10 (20.8)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>13 (27.1)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>35 (72.9)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>Nottingham- Barcelona</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0–1</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>46 (86.8)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>7(13.2)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.154</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>16 (30.2)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>37 (69.8)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.229</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>2–3</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>45 (76.3)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>14 (23.7)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>12 (20.3)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>47(79.7)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1" morerows="1">
                            <SimplePara>MSKCC class</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>1</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>21 (100)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0 (0)</SimplePara>
                          </entry>
                          <entry colname="c5" morerows="1">
                            <SimplePara>0.012<Superscript>b</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>10 (47.6)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>11 (52.4)</SimplePara>
                          </entry>
                          <entry colname="c8" morerows="1">
                            <SimplePara>0.008</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c2">
                            <SimplePara>2–3</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>70 (76.9)</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>21 (23.1)</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>18 (19.8)</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>73 (80.2)</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                    <tfooter>
                      <SimplePara>
                                    <Emphasis Type="Italic">Abbreviations</Emphasis>: <Emphasis Type="Italic">ECOG PS</Emphasis> The Eastern Cooperative Oncology Group performance score, <Emphasis Type="Italic">KPS</Emphasis> Karnofsky performance status score, <Emphasis Type="Italic">LDH</Emphasis> lactate dehydrogenase, <Emphasis Type="Italic">GCB</Emphasis> germinal center B cell-like, <Emphasis Type="Italic">CSF</Emphasis> cerebrospinal fluid, <Emphasis Type="Italic">IELSG</Emphasis> the International Extranodal Lymphoma Study group, <Emphasis Type="Italic">MSKCC</Emphasis> Memorial Sloan Kettering Cancer Center</SimplePara>
                      <SimplePara>
                                    <Superscript>a</Superscript>Some cases have missing values that lacked the information about the variables</SimplePara>
                      <SimplePara>
                                    <Superscript>b</Superscript>Fisher’s exact test</SimplePara>
                    </tfooter>
                  </Table>
                        </Para>
              </Section2>
              <Section2 ID="Sec9">
                <Heading>Prognostic significance of MYC, BCL2 and BCL6 expression</Heading>
                <Para ID="Par16">Kaplan-Meier survival analysis demonstrated that MYC expression (cutoff score 40) was significantly associated with a shorter PFS (<Emphasis Type="Italic">P</Emphasis> = 0.027) in patients with PCNS-DLBCL (Fig. <InternalRef RefID="Fig2">2a</InternalRef>), but not with OS (Fig. <InternalRef RefID="Fig2">2b</InternalRef>). In contrast, higher BCL2 expression was significantly related to a shorter OS (<Emphasis Type="Italic">P</Emphasis> = 0.010 with a cutoff score of 30 and <Emphasis Type="Italic">P</Emphasis> = 0.031 with a cutoff score 60), but was not related to PFS (Fig. <InternalRef RefID="Fig2">2c-f</InternalRef>). BCL6 expression had no prognostic significance. Patients who were negative for both MYC and BCL2 (cutoff score 30) showed better OS than patients positive for either (<Emphasis Type="Italic">P</Emphasis> = 0.014) (Fig. <InternalRef RefID="Fig3">3a and b</InternalRef>). Patients with dual positivity for MYC and BCL2 (cutoff score 30) exhibited worse PFS than that of the others (<Emphasis Type="Italic">P</Emphasis> = 0.041) (Fig. <InternalRef RefID="Fig3">3c and d</InternalRef>), but its statistical significance was lower than that observed by comparing MYC expression status alone (Fig. <InternalRef RefID="Fig2">2a</InternalRef>). After incorporating both age and prognostic score into a multivariate analysis, MYC and BCL2 expression lost its prognostic impact, and a higher Nottingham-Barcelona score (≥2) and age remained as independent prognostic indicators for PFS (<Emphasis Type="Italic">P</Emphasis> = 0.032) and OS (<Emphasis Type="Italic">P</Emphasis> = 0.044), respectively (Table <InternalRef RefID="Tab3">3</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig2">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Progression-free survival (PFS) and overall survival (OS) of patients with PCNS-DLBCL according to MYC or BCL2 expression status. <Emphasis Type="Bold">a</Emphasis> and <Emphasis Type="Bold">b</Emphasis> PFS and OS according to MYC protein expression status (cutoff score 40) are plotted using the Kaplan-Meier method and analyzed by the log-rank test. PFS and OS according to BCL2 protein expression status using a cutoff score of 30 (<Emphasis Type="Bold">c</Emphasis> and <Emphasis Type="Bold">d</Emphasis>), or with a cutoff score of 60 (<Emphasis Type="Bold">e</Emphasis> and <Emphasis Type="Bold">f</Emphasis>) are plotted using the Kaplan-Meier method and analyzed by the log-rank test</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO2">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12885_2016_2397_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                           <Figure Category="Standard" Float="Yes" ID="Fig3">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Progression-free survival (PFS) and overall survival (OS) of patients with PCNS-DLBCL according to combined MYC and BCL2 expression status. <Emphasis Type="Bold">a</Emphasis> and <Emphasis Type="Bold">b</Emphasis> PFS and OS of patients without expression for either MYC or BCL2 (double-negative) versus other groups are plotted using the Kaplan-Meier method and analyzed by the log-rank test. <Emphasis Type="Bold">c</Emphasis> and <Emphasis Type="Bold">d</Emphasis> PFS and OS of patients with concomitant MYC and BCL2 expression (double-positive) versus other groups are plotted using the Kaplan-Meier method and analyzed by the log-rank test. <Emphasis Type="Bold">e</Emphasis> and <Emphasis Type="Bold">f</Emphasis> PFS and OS of patients treated with combined MVP and radiotherapy according to the MYC and BCL2 expression status were plotted using the Kaplan-Meier method and analyzed by the log-rank test</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO3">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12885_2016_2397_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                           <Table Float="Yes" ID="Tab3">
                    <Caption Language="En">
                      <CaptionNumber>Table 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Multivariate analysis of MYC expression and prognostic scoring systems for progression-free survival and overall survival in all patients with PCNS-DLBCL</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="8">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <colspec align="left" colname="c7" colnum="7"/>
                      <colspec align="left" colname="c8" colnum="8"/>
                      <thead>
                        <row>
                          <entry colname="c1"/>
                          <entry nameend="c4" namest="c2">
                            <SimplePara>PFS</SimplePara>
                          </entry>
                          <entry nameend="c8" namest="c5">
                            <SimplePara>OS</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1"/>
                          <entry colname="c2">
                            <SimplePara>HR</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>95 % CI</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>
                              <Emphasis Type="Italic">P</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry colname="c5"/>
                          <entry colname="c6">
                            <SimplePara>HR</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>95 % CI</SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>
                              <Emphasis Type="Italic">P</Emphasis>
                            </SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry colname="c1">
                            <SimplePara>Age</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0.989</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>0.949-1.032</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.614</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>Age</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>1.074</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>1.002–1.151</SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>0.044</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>MYC ≥ 40</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>1.745</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>0.848–3.589</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.130</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>BCL2 ≥ 30</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>-<Superscript>a</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>-<Superscript>a</Superscript>
                                          </SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>0.951</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>N-B, 2-3</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>2.243</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>1.072–4.693</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.032</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>N-B, 2-3</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>1.392</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>0.474–4.084</SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>0.547</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>MSKCC, 2–3</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>2.635</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>0.502–13.827</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.252</SimplePara>
                          </entry>
                          <entry colname="c5">
                            <SimplePara>MSKCC, 2–3</SimplePara>
                          </entry>
                          <entry colname="c6">
                            <SimplePara>0.370</SimplePara>
                          </entry>
                          <entry colname="c7">
                            <SimplePara>0.048–2.841</SimplePara>
                          </entry>
                          <entry colname="c8">
                            <SimplePara>0.339</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                    <tfooter>
                      <SimplePara>
                                    <Emphasis Type="Italic">Abbreviations</Emphasis>: <Emphasis Type="Italic">PFS</Emphasis> progression-free survival, <Emphasis Type="Italic">OS</Emphasis> overall survival, <Emphasis Type="Italic">HR</Emphasis> hazard ratio, <Emphasis Type="Italic">CI</Emphasis> confidence interval, <Emphasis Type="Italic">N-B</Emphasis> Nottingham-Barcelona, <Emphasis Type="Italic">MSKCC</Emphasis> Memorial Sloan Kettering Cancer Center</SimplePara>
                      <SimplePara>(<Superscript>a</Superscript>values are not shown.)</SimplePara>
                    </tfooter>
                  </Table>
                        </Para>
                <Para ID="Par17">Among patients with PCNS-DLBCL treated with MVP-RT, MYC expression (cutoff score of 40) was associated with a shorter PFS (<Emphasis Type="Italic">P</Emphasis> = 0.011) (Additional file <InternalRef RefID="MOESM3">3</InternalRef>: Figure S2). BCL2 overexpression (cutoff score of 60) was significantly related to a shorter OS (<Emphasis Type="Italic">P</Emphasis> = 0.025) (Additional file <InternalRef RefID="MOESM3">3</InternalRef>: Figure S2). In the MVP-RT group, patients with dual positivity for MYC and BCL2 (cutoff score of 60) exhibited worse PFS than that of the others (<Emphasis Type="Italic">P</Emphasis> &lt;0.001) (Fig. <InternalRef RefID="Fig3">3e</InternalRef>), and those who were negative for both MYC and BCL2 (cutoff score of 60) showed better OS than that of patients positive for either (<Emphasis Type="Italic">P</Emphasis> = 0.033) (Fig. <InternalRef RefID="Fig3">3f</InternalRef>). Furthermore, in multivariate analysis, MYC and BCL2 coexpression was an independent factor for poor PFS (<Emphasis Type="Italic">P</Emphasis> = 0.010; hazard ratio = 4.372) (Table <InternalRef RefID="Tab4">4</InternalRef>).<Table Float="Yes" ID="Tab4">
                    <Caption Language="En">
                      <CaptionNumber>Table 4</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Multivariate analysis of MYC and BCL2 coexpression and prognostic scoring systems for progression-free survival in patients with PCNS-DLBCL treated with combined MVP and radiotherapy</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="4">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <thead>
                        <row>
                          <entry colname="c1"/>
                          <entry nameend="c4" namest="c2">
                            <SimplePara>PFS</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1"/>
                          <entry colname="c2">
                            <SimplePara>HR</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>95 % CI</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>
                              <Emphasis Type="Italic">P</Emphasis>
                            </SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry colname="c1">
                            <SimplePara>Age</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>0.983</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>0.922–1.049</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.605</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>N-B, 2–3</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>1.146</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>0.464–2.830</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.768</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>MSKCC, 2–3</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>4.975</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>0.715–34.613</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.105</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry colname="c1">
                            <SimplePara>MYC (≥40) and BCL2 (≥60), dual positive</SimplePara>
                          </entry>
                          <entry colname="c2">
                            <SimplePara>4.372</SimplePara>
                          </entry>
                          <entry colname="c3">
                            <SimplePara>1.430–13.367</SimplePara>
                          </entry>
                          <entry colname="c4">
                            <SimplePara>0.010</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                    <tfooter>
                      <SimplePara>
                                    <Emphasis Type="Italic">Abbreviations</Emphasis>: <Emphasis Type="Italic">PFS</Emphasis> progression-free survival, <Emphasis Type="Italic">HR</Emphasis> hazard ratio, <Emphasis Type="Italic">CI</Emphasis> confidence interval, <Emphasis Type="Italic">N-B</Emphasis> Nottingham- Barcelona, <Emphasis Type="Italic">MSKCC</Emphasis> Memorial Sloan Kettering Cancer Center</SimplePara>
                    </tfooter>
                  </Table>
                        </Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec10" Type="Discussion">
              <Heading>Discussion</Heading>
              <Para ID="Par18">This study demonstrated that MYC and BCL2 overexpression was significantly associated with a high MSKCC class, and was related to shorter PFS and OS in patients with PCNS-DLBCL.</Para>
              <Para ID="Par19">This study showed that MYC overexpression was associated with poor PFS in PCNS-DLBCL, which was partly consistent with Tapia et al.’s study [<CitationRef CitationID="CR10">10</CitationRef>], but different from previous reports by Brunn et al. and Gill et al. [<CitationRef CitationID="CR8">8</CitationRef>, <CitationRef CitationID="CR9">9</CitationRef>]. Tapia et al. reported that MYC overexpression (using a cutoff score of 30) was related to poor OS, while the latter studies showed that MYC expression was not associated with PCNS-DLBCL prognosis. In this study, the mean MYC expression score was 18.16 ± 19.58 and the MYC positive rate using a cutoff score of 40 was 18.1 %, which were much lower than those observed in previous reports. Previous studies on PCNS-DLBCL reported a mean MYC expression score of 29–50 and MYC positive rates ranging from 43 to 82 % with cutoff values of 30 or 40, and an unreported cutoff score in one case [<CitationRef CitationID="CR8">8</CitationRef>–<CitationRef CitationID="CR10">10</CitationRef>]. However, antibody and racial differences (Western <Emphasis Type="Italic">vs.</Emphasis> Asian) may account for these discrepancies.</Para>
              <Para ID="Par20">MYC immunostaining in systemic DLBCLs, particularly in cases without <Emphasis Type="Italic">MYC</Emphasis> gene translocation, is heterogeneous. Thus, the feasibility of interpreting and scoring MYC expression using IHC in DLBCL has been questioned [<CitationRef CitationID="CR13">13</CitationRef>]. We performed <Emphasis Type="Italic">MYC</Emphasis> fluorescence in situ hybridization in PCNS-DLBCL cases with MYC overexpression as reported previously [<CitationRef CitationID="CR14">14</CitationRef>]. Of note, in this study, only 2 (12 %) of 17 patients with MYC overexpression had a <Emphasis Type="Italic">MYC</Emphasis> translocation, and another two patients showed increased <Emphasis Type="Italic">MYC</Emphasis> copy number (ICN) (Additional file <InternalRef RefID="MOESM2">2</InternalRef>: Table S2). In contrast, approximately 25 % of the MYC overexpressing systemic DLBCLs showed <Emphasis Type="Italic">MYC</Emphasis> gene translocation [<CitationRef CitationID="CR15">15</CitationRef>]. Thus, translocation and ICN did not appear to explain MYC overexpression in most cases of PCNS-DLBCL, consistent with a previous report [<CitationRef CitationID="CR10">10</CitationRef>]. MYC overexpression in PCNS-DLBCL might result from other mechanisms such as a mutation of <Emphasis Type="Italic">MYC</Emphasis> and post-transcriptional or post-translational regulation. In addition, post-genetic or epigenetic regulation of MYC expression in PCNS-DLBCL may lead to heterogeneous MYC immunostaining. Meanwhile, concordance of MYC scoring between hematopathologists was much lower when interpreting entire tissue sections rather than a tissue microarray using a 1-mm core [<CitationRef CitationID="CR13">13</CitationRef>]. In this study, whole tissue sections were used and the largest series of patients with PCNS-DLBCL was evaluated based on treatment modality, and MYC overexpression was found to have prognostic value.</Para>
              <Para ID="Par21">The rate of BCL2 expression in PCNS-DLBCL varies, which might also be attributable to the use of different antibodies and different cutoff values for determining overexpression [<CitationRef CitationID="CR8">8</CitationRef>, <CitationRef CitationID="CR9">9</CitationRef>, <CitationRef CitationID="CR16">16</CitationRef>–<CitationRef CitationID="CR19">19</CitationRef>]. Previous studies reported a wide range of BCL2 expression rates (56–92 %) with various cutoff scores from 25–70. We observed that 75.0 % (87/114) of PCNS-DLBCL cases were BCL2-positive using a cutoff score of 30, similar to a previous report by Tapia et al. [<CitationRef CitationID="CR10">10</CitationRef>]. In their study, BCL2 positivity was observed in 71 % of PCNS-DLBCL cases, but had no relationship with prognosis [<CitationRef CitationID="CR10">10</CitationRef>]. In contrast, the present study demonstrated that patients with PCNS-DLBCL and BCL2 overexpression tended to have a shorter PFS and had significantly poorer OS, suggesting that BCL2 may potentially be used as a prognostic marker.</Para>
              <Para ID="Par22">In this study, MYC and BCL2 expression lost their prognostic significance after multivariate analysis. This may be partly attributable to the fact that MYC and BCL2 expression was significantly associated with higher MSKCC class. The MYC and BCL2 coexpression rate was 15.8 % (18/114) of PCNS-DLBCLs, which was much lower than values from previous studies including 29 % (12/41), 60 % (35/59) and 82 % (41/50) of PCNS-DLBCLs and 34 % (157/466) of systemic DLBCLs [<CitationRef CitationID="CR7">7</CitationRef>–<CitationRef CitationID="CR10">10</CitationRef>], but was similar to the rate (21 % [64/304]) reported in another study on systemic DLBCLs [<CitationRef CitationID="CR6">6</CitationRef>]. In this study, patients with PCNS-DLBCL and concomitant MYC and BCL2 overexpression showed poor PFS (<Emphasis Type="Italic">P</Emphasis> = 0.041), and those lacking both MYC and BCL2 overexpression had a prolonged OS (<Emphasis Type="Italic">P</Emphasis> = 0.014). However, the statistical significance of MYC and BCL2 dual-positivity on the PFS of patients was diminished compared to MYC positivity alone (<Emphasis Type="Italic">P</Emphasis> = 0.027). Similar to the present study, Tapia et al. reported that high MYC expression was associated with a lower OS, but that concurrent expression of MYC and BCL2 showed a tendency towards a lower OS with no statistical significance [<CitationRef CitationID="CR10">10</CitationRef>]. However, in this study, when analyzed in patients with PCNS-DLBCL treated with combined MVP and radiotherapy, MYC and BCL2 dual-positivity was an independent prognostic factor for poor PFS. Thus, MYC and BCL2 coexpression in PCNS-DLBCL seems to have prognostic value, although it is limited compared with systemic DLBCL.</Para>
              <Para ID="Par23">Several previous studies are available on BCL6 expression and its prognostic impact on PCNS-DLBCL. BCL6 expression rates from 46 to 79 % of PCNS-DLBCL cases with cutoff scores from 10–60 have been reported [<CitationRef CitationID="CR16">16</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>, <CitationRef CitationID="CR20">20</CitationRef>–<CitationRef CitationID="CR22">22</CitationRef>]. The prognostic implications of BCL6 for PCNS-DLBCL are largely conflicting [<CitationRef CitationID="CR10">10</CitationRef>, <CitationRef CitationID="CR16">16</CitationRef>, <CitationRef CitationID="CR19">19</CitationRef>–<CitationRef CitationID="CR25">25</CitationRef>]. The results of this study further suggest that BCL6 may have little, if any, prognostic value for PCNS-DLBCL. Non-GCB phenotype tumors were the predominant PCNS-DLBCL type in this study, and no association between cell of origin and prognosis was found, which is consistent with previous reports [<CitationRef CitationID="CR9">9</CitationRef>, <CitationRef CitationID="CR26">26</CitationRef>, <CitationRef CitationID="CR27">27</CitationRef>]. Unexpectedly, patients with high serum LDH levels had a more favorable PFS than that of patients with normal serum LDH levels. In addition, the results of this study show that alleged prognostic scoring systems, including Nottingham-Barcelona and MSKCC, reflect PFS but not OS. The reason for these discrepancies is not known, and we were unable to deduce the reasons over the course of this study; however, these results might support the idea that PCNS-DLBCL prognosis is dependent on multiple, complex factors. This study has some limitations. It was a retrospective study, and therapeutic modalities were not completely homogeneous between patients. However, to the best of our knowledge, this study is the largest performed on the expression of MYC, BCL2 and BCL6 PCNS-DLBCL with long-term follow up, and the first report on the relationship of these factors to clinicopathological features in Asian patients.</Para>
            </Section1>
            <Section1 ID="Sec11" Type="Conclusion">
              <Heading>Conclusions</Heading>
              <Para ID="Par24">This study demonstrated that the expression of MYC and BCL2 may be of prognostic value in patients with PCNS-DLBCL when combined with existing prognostic tools and factors.</Para>
            </Section1>
            <Section1 ID="Sec12">
              <Heading>Abbreviations</Heading>
              <Para ID="Par25">CHOD/BVAM, cyclophosphamide, doxorubicin, vincristine and dexamethasone/bis-chloronitrosourea, cytosine arabinoside and methotrexate; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CI, confidence interval; CNS, central nervous system; COPADM, cyclophosphamide, vincristine, prednisolone, doxorubicin and methotrexate; CSF, cerebrospinal fluid; DLBCL, diffuse large B-cell lymphoma; ECOG PS, The Eastern Cooperative Oncology Group performance score; GCB, germinal center B-cell-like; GTR, grossly total resection; HD-MTX, high-dose methotrexate; HR, hazard ratio; IELSG, The international extranodal lymphoma study group; IHC, immunohistochemistry; IPI, international prognostic index; IT-MTX, intrathecal methotrexate; KPS, Karnofsky Performance Status score; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center; MVP, combined chemotherapy regimen of high-dose methotrexate, vincristine and procarbazine; N-B, Nottingham- Barcelona; OS, overall survival; PCNS-DLBCL, primary diffuse large B-cell lymphoma of the central nervous system; PFS, progression-free survival; RT, radiotherapy; STR, subtotal resection; WHO, World Health Organization; yr, year</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/12885_2016_Article_2397.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Acknowledgments>
              <Heading>Acknowledgements</Heading>
              <SimplePara>Not applicable.</SimplePara>
              <FormalPara ID="FPar1" RenderingStyle="Style1">
                <Heading>Funding</Heading>
                <Para ID="Par26">This research was supported by the Basic Science Research Program (grant No.: NRF-2013R1A1A2013210) and the Global Core Research Center (GCRC) (grant No. 2012–0001190) through the National Research Foundation (NRF) funded by the Ministry of Education, Science and Technology (MEST), Republic of Korea.</Para>
              </FormalPara>
              <FormalPara ID="FPar2" RenderingStyle="Style1">
                <Heading>Availability of data and materials</Heading>
                <Para ID="Par27">The dataset supporting the conclusions of this article is included within the article and its additional file (Additional file <InternalRef RefID="MOESM4">4</InternalRef>: Dataset of 114 patients with PCNS-DLBCL (XLSX 60.6 kb)).</Para>
              </FormalPara>
              <FormalPara ID="FPar3" RenderingStyle="Style1">
                <Heading>Authors’ contributions</Heading>
                <Para ID="Par28">SK, SJN, and YKJ designed research, acquired pathologic data, analyzed pathologic and clinical data and wrote the manuscript; DW, HK, SHP, and CWK acquired and analyzed pathologic data and wrote the manuscript; EL, TMK, and DSH acquired and analyzed clinical data, and wrote the manuscript. All authors read and approved the final manuscript.</Para>
              </FormalPara>
              <FormalPara ID="FPar4" RenderingStyle="Style1">
                <Heading>Authors’ information</Heading>
                <Para ID="Par29">Not further applicable.</Para>
              </FormalPara>
              <FormalPara ID="FPar5" RenderingStyle="Style1">
                <Heading>Competing interests</Heading>
                <Para ID="Par30">The authors declare that they have no competing interests.</Para>
              </FormalPara>
              <FormalPara ID="FPar6" RenderingStyle="Style1">
                <Heading>Consent for publication</Heading>
                <Para ID="Par31">Not applicable.</Para>
              </FormalPara>
              <FormalPara ID="FPar7" RenderingStyle="Style1">
                <Heading>Ethics approval and consent to participate</Heading>
                <Para ID="Par32">This study followed the World Medical Association Declaration of Helsinki recommendations and was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (SNUH) (IRB No. 1506-080-681). Informed consent for participation in the study was waived by the IRB of SNUH on the basis that this study was a retrospective study using archived material and did not pose increased risk to the patients.</Para>
              </FormalPara>
            </Acknowledgments>
            <Appendix ID="App1" OutputMedium="Online">
              <Section1 ID="Sec13">
                <Heading>Additional files</Heading>
                <Para ID="Par33">
                  <MediaObject ID="MOESM1">
                    <DataObject FileRef="MediaObjects/12885_2016_2397_MOESM1_ESM.ppt">
                      <Caption Language="En">
                        <CaptionNumber>Additional file 1: Figure S1.</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Correlation of MYC, BCL2 and BCL6 IHC score. Correlations between MYC and BCL2 (left upper), MYC and BCL6 (right upper), and BCL2 and BCL6 (lower) IHC score was compared using Spearman correlation test. (PPT 343 kb)</SimplePara>
                        </CaptionContent>
                      </Caption>
                    </DataObject>
                  </MediaObject>
                  <MediaObject ID="MOESM2">
                    <DataObject FileRef="MediaObjects/12885_2016_2397_MOESM2_ESM.docx">
                      <Caption Language="En">
                        <CaptionNumber>Additional file 2:</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>
                                          <Emphasis Type="Bold">Table S1.</Emphasis> Correlation of BCL6 expression and clinicopathological variables; <Emphasis Type="Bold">Table S2.</Emphasis> MYC translocation and copy number change in MYC positive cases. (DOCX 24 kb)</SimplePara>
                        </CaptionContent>
                      </Caption>
                    </DataObject>
                  </MediaObject>
                  <MediaObject ID="MOESM3">
                    <DataObject FileRef="MediaObjects/12885_2016_2397_MOESM3_ESM.tif">
                      <Caption Language="En">
                        <CaptionNumber>Additional file 3: Figure S2.</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Progression-free survival (PFS) and overall survival (OS) of patients with PCNS-DLBCL treated with MVP-RT according to MYC or BCL2 expression status. (A and B) PFS and OS according to MYC protein expression status (cutoff score 40) are plotted using the Kaplan-Meier method and analyzed by the log-rank test. PFS and OS according to BCL2 protein expression status using a cutoff score of 30 (C and D), or with a cutoff score of 60 (E and F) are plotted using the Kaplan-Meier method and analyzed by the log-rank test. (TIF 12287 kb)</SimplePara>
                        </CaptionContent>
                      </Caption>
                    </DataObject>
                  </MediaObject>
                  <MediaObject ID="MOESM4">
                    <DataObject FileRef="MediaObjects/12885_2016_2397_MOESM4_ESM.xlsx">
                      <Caption Language="En">
                        <CaptionNumber>Additional file 4:</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Dataset of 114 patients with PCNS-DLBCL. (XLSX 56 kb)</SimplePara>
                        </CaptionContent>
                      </Caption>
                    </DataObject>
                  </MediaObject>
                </Para>
              </Section1>
            </Appendix>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>SH</Initials>
                    <FamilyName>Swerdlow</FamilyName>
                  </BibAuthorName>
                  <InstitutionalAuthorName>International Agency for Research on C, World Health O</InstitutionalAuthorName>
                  <Year>2008</Year>
                  <BookTitle>WHO classification of tumours of haematopoietic and lymphoid tissues</BookTitle>
                  <PublisherName>International Agency for Research on Cancer</PublisherName>
                  <PublisherLocation>Lyon</PublisherLocation>
                </BibBook>
                <BibUnstructured>Swerdlow SH, International Agency for Research on C, World Health O. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bhagavathi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Sharathkumar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Hunter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Sung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Kanhere</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MD</Initials>
                    <FamilyName>Venturina</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Wilson</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas</ArticleTitle>
                  <JournalTitle>Clinical neuropathology</JournalTitle>
                  <VolumeID>27</VolumeID>
                  <IssueID>1</IssueID>
                  <FirstPage>13</FirstPage>
                  <LastPage>20</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD1c7gtVejug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.5414/NPP27013</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18257470</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bhagavathi S, Sharathkumar A, Hunter S, Sung L, Kanhere R, Venturina MD, Wilson JD Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clinical neuropathology. 2008;27(1):13–20.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AJ</Initials>
                    <FamilyName>Ferreri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JY</Initials>
                    <FamilyName>Blay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Reni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Pasini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Spina</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ambrosetti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Calderoni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Rossi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Vavassori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Conconi</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience</ArticleTitle>
                  <JournalTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>266</FirstPage>
                  <LastPage>72</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2003.09.139</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(2):266–72.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Bessell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Graus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Lopez-Guillermo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Lewis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Villa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Verger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Petit</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors</ArticleTitle>
                  <JournalTitle>International journal of radiation oncology, biology, physics</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>501</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ijrobp.2003.11.001</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15145169</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J. Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. International journal of radiation oncology, biology, physics. 2004;59(2):501–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LE</Initials>
                    <FamilyName>Abrey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Ben-Porat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KS</Initials>
                    <FamilyName>Panageas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Yahalom</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Berkey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Curran</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Schultz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Leibel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Nelson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Mehta</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model</ArticleTitle>
                  <JournalTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <IssueID>36</IssueID>
                  <FirstPage>5711</FirstPage>
                  <LastPage>5</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2006.08.2941</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(36):5711–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NA</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GW</Initials>
                    <FamilyName>Slack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KJ</Initials>
                    <FamilyName>Savage</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Connors</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Ben-Neriah</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rogic</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DW</Initials>
                    <FamilyName>Scott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KL</Initials>
                    <FamilyName>Tan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Steidl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LH</Initials>
                    <FamilyName>Sehn</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone</ArticleTitle>
                  <JournalTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <IssueID>28</IssueID>
                  <FirstPage>3452</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhslSksrfI</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2011.41.0985</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(28):3452–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Hu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ZY</Initials>
                    <FamilyName>Xu-Monette</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Tzankov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Green</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Balasubramanyam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WM</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Visco</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RN</Initials>
                    <FamilyName>Miranda</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>121</VolumeID>
                  <IssueID>20</IssueID>
                  <FirstPage>4021</FirstPage>
                  <LastPage>31</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXot1Kjs7Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood-2012-10-460063</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23449635</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3709650</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Brunn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Nagel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Montesinos-Rongen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Klapper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Vater</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Paulus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Hans</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Blumcke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Weis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Siebert</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas</ArticleTitle>
                  <JournalTitle>Acta neuropathologica</JournalTitle>
                  <VolumeID>126</VolumeID>
                  <IssueID>4</IssueID>
                  <FirstPage>603</FirstPage>
                  <LastPage>5</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00401-013-1169-7</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24061549</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Brunn A, Nagel I, Montesinos-Rongen M, Klapper W, Vater I, Paulus W, Hans V, Blumcke I, Weis J, Siebert R, et al. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta neuropathologica. 2013;126(4):603–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KZ</Initials>
                    <FamilyName>Gill</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Iwamoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Allen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Hoehn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VV</Initials>
                    <FamilyName>Murty</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Alobeid</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Bhagat</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system</ArticleTitle>
                  <JournalTitle>PloS one</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <IssueID>12</IssueID>
                  <FirstPage>e114398</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0114398</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>25479599</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4257680</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gill KZ, Iwamoto F, Allen A, Hoehn D, Murty VV, Alobeid B, Bhagat G. MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. PloS one. 2014;9(12):e114398.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>Tapia G, Baptista MJ, Munoz-Marmol AM, Gaafar A, Puente-Pomposo M, Garcia O, Garcia O, Marginet-Flinch R, Sanz C, Navarro JT, Sancho JM, et al. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2015;123(7):596–603.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CP</Initials>
                    <FamilyName>Hans</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DD</Initials>
                    <FamilyName>Weisenburger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TC</Initials>
                    <FamilyName>Greiner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RD</Initials>
                    <FamilyName>Gascoyne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Delabie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Ott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HK</Initials>
                    <FamilyName>Muller-Hermelink</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Campo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Braziel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ES</Initials>
                    <FamilyName>Jaffe</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>103</VolumeID>
                  <IssueID>1</IssueID>
                  <FirstPage>275</FirstPage>
                  <LastPage>82</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhsFGhsA%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood-2003-05-1545</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>14504078</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Paik</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SJ</Initials>
                    <FamilyName>Nam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TM</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Heo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CW</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YK</Initials>
                    <FamilyName>Jeon</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas</ArticleTitle>
                  <JournalTitle>BMC cancer</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>911</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1471-2407-14-911</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>25472725</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4265452</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Paik JH, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK. Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas. BMC cancer. 2014;14:911.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AZ</Initials>
                    <FamilyName>Mahmoud</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TI</Initials>
                    <FamilyName>George</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DR</Initials>
                    <FamilyName>Czuchlewski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>QY</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CS</Initials>
                    <FamilyName>Wilson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CE</Initials>
                    <FamilyName>Sever</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AG</Initials>
                    <FamilyName>Bakhirev</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NL</Initials>
                    <FamilyName>Steidler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KK</Initials>
                    <FamilyName>Reichard</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists</ArticleTitle>
                  <JournalTitle>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <IssueID>4</IssueID>
                  <FirstPage>545</FirstPage>
                  <LastPage>51</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2cXhvF2mtbzO</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/modpathol.2014.140</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mahmoud AZ, George TI, Czuchlewski DR, Zhang QY, Wilson CS, Sever CE, Bakhirev AG, Zhang D, Steidler NL, Reichard KK, et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015;28(4):545–51.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SO</Initials>
                    <FamilyName>Yoon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YK</Initials>
                    <FamilyName>Jeon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Paik</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WY</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YA</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JE</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CW</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type</ArticleTitle>
                  <JournalTitle>Histopathology</JournalTitle>
                  <VolumeID>53</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>205</FirstPage>
                  <LastPage>17</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD1crkvVWrsg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1365-2559.2008.03076.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18752503</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–17.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TM</Initials>
                    <FamilyName>Green</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KH</Initials>
                    <FamilyName>Young</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Visco</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ZY</Initials>
                    <FamilyName>Xu-Monette</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Orazi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Go</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Nielsen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>OV</Initials>
                    <FamilyName>Gadeberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Mourits-Andersen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Frederiksen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone</ArticleTitle>
                  <JournalTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <IssueID>28</IssueID>
                  <FirstPage>3460</FirstPage>
                  <LastPage>7</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhslSksrfJ</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2011.41.4342</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(28):3460–7.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Levy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Deangelis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Filippa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KS</Initials>
                    <FamilyName>Panageas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LE</Initials>
                    <FamilyName>Abrey</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Bcl-6 predicts improved prognosis in primary central nervous system lymphoma</ArticleTitle>
                  <JournalTitle>Cancer</JournalTitle>
                  <VolumeID>112</VolumeID>
                  <IssueID>1</IssueID>
                  <FirstPage>151</FirstPage>
                  <LastPage>6</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/cncr.23149</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17999414</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer. 2008;112(1):151–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Tapia</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Baptista</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Munoz-Marmol</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Gaafar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Puente-Pomposo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Garcia</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Marginet-Flinch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Sanz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Navarro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Sancho</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system</ArticleTitle>
                  <JournalTitle>Apmis</JournalTitle>
                  <VolumeID>123</VolumeID>
                  <IssueID>7</IssueID>
                  <FirstPage>596</FirstPage>
                  <LastPage>603</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2MXhtVOiurzF</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/apm.12390</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26010683</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tapia G, Baptista MJ, Munoz-Marmol AM, Gaafar A, Puente-Pomposo M, Garcia O, Marginet-Flinch R, Sanz C, Navarro JT, Sancho JM, et al. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Apmis. 2015;123(7):596–603.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CH</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KT</Initials>
                    <FamilyName>Kuo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Chuang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SH</Initials>
                    <FamilyName>Kuo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KC</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Hsu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HF</Initials>
                    <FamilyName>Tien</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AL</Initials>
                    <FamilyName>Cheng</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin</ArticleTitle>
                  <JournalTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <IssueID>4</IssueID>
                  <FirstPage>1152</FirstPage>
                  <LastPage>6</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhsFalt7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1078-0432.CCR-05-1699</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC, Hsu HC, Tien HF, Cheng AL. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(4):1152–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Camilleri-Broet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Criniere</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Broet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Delwail</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Mokhtari</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Moreau</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Kujas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Raphael</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Iraqi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Sautes-Fridman</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>107</VolumeID>
                  <IssueID>1</IssueID>
                  <FirstPage>190</FirstPage>
                  <LastPage>6</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhsVGmsw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood-2005-03-1024</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16150948</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Lossos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bayraktar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Weinzierl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SF</Initials>
                    <FamilyName>Younes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PJ</Initials>
                    <FamilyName>Hosein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RJ</Initials>
                    <FamilyName>Tibshirani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Sutton Posthumus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>DeAngelis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Raizer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Schiff</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma</ArticleTitle>
                  <JournalTitle>British journal of haematology</JournalTitle>
                  <VolumeID>165</VolumeID>
                  <IssueID>5</IssueID>
                  <FirstPage>640</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2cXotFOhsrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/bjh.12801</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24571259</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4123533</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lossos C, Bayraktar S, Weinzierl E, Younes SF, Hosein PJ, Tibshirani RJ, Sutton Posthumus J, DeAngelis LM, Raizer J, Schiff D, et al. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. British journal of haematology. 2014;165(5):640–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Braaten</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Betensky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Leval</FamilyName>
                    <Particle>de</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Okada</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FH</Initials>
                    <FamilyName>Hochberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DN</Initials>
                    <FamilyName>Louis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NL</Initials>
                    <FamilyName>Harris</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TT</Initials>
                    <FamilyName>Batchelor</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma</ArticleTitle>
                  <JournalTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <IssueID>3</IssueID>
                  <FirstPage>1063</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXhvFKitL0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003;9(3):1063–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Kreher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Johrens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Strehlow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Martus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Borowiec</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Radke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Heppner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Roth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Thiel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Pietsch</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma</ArticleTitle>
                  <JournalTitle>Neuro-oncology</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <IssueID>7</IssueID>
                  <FirstPage>1016</FirstPage>
                  <LastPage>21</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/neuonc/nov046</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>25817328</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kreher S, Johrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, et al. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-oncology. 2015;17(7):1016–21.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Rubenstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ED</Initials>
                    <FamilyName>Hsi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SH</Initials>
                    <FamilyName>Jung</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MO</Initials>
                    <FamilyName>Nakashima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Grant</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BD</Initials>
                    <FamilyName>Cheson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LD</Initials>
                    <FamilyName>Kaplan</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)</ArticleTitle>
                  <JournalTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <IssueID>25</IssueID>
                  <FirstPage>3061</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXhs1SisbrI</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1200/JCO.2012.46.9957</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(25):3061–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Momota</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Narita</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Maeshima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Miyakita</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Shinomiya</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Maruyama</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Muragaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Shibui</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma</ArticleTitle>
                  <JournalTitle>Journal of neuro-oncology</JournalTitle>
                  <VolumeID>98</VolumeID>
                  <IssueID>3</IssueID>
                  <FirstPage>341</FirstPage>
                  <LastPage>8</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXntlKlsbo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s11060-009-0078-z</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20012911</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Momota H, Narita Y, Maeshima AM, Miyakita Y, Shinomiya A, Maruyama T, Muragaki Y, Shibui S. Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. Journal of neuro-oncology. 2010;98(3):341–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Kampalath</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Schultz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Bunyi-Teopengco</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Logan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Eshoa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AP</Initials>
                    <FamilyName>Dincer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Perkins</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals</ArticleTitle>
                  <JournalTitle>Archives of pathology &amp; laboratory medicine</JournalTitle>
                  <VolumeID>127</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>208</FirstPage>
                  <LastPage>12</LastPage>
                </BibArticle>
                <BibUnstructured>Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Archives of pathology &amp; laboratory medicine. 2003;127(2):208–12.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibUnstructured>Raoux D, Duband S, Forest F, Trombert B, Chambonniere ML, Dumollard JM, Khaddage A, Gentil-Perret A, Peoc'h M. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. Neuropathology : official journal of the Japanese Society of Neuropathology. 2010;30(3):232–40.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Hattab</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SE</Initials>
                    <FamilyName>Martin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Al-Khatib</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Kupsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GH</Initials>
                    <FamilyName>Vance</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Stohler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Czader</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Al-Abbadi</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases</ArticleTitle>
                  <JournalTitle>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>235</FirstPage>
                  <LastPage>43</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/modpathol.2009.164</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hattab EM, Martin SE, Al-Khatib SM, Kupsky WJ, Vance GH, Stohler RA, Czader M, Al-Abbadi MA. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2010;23(2):235–43.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
